BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Frequently asked questions
What sector does BioAtla, Inc (BCAB) operate in?
BioAtla, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BioAtla, Inc (BCAB) current stock price?
As of the latest data, BioAtla, Inc stock price is $3.09, with a previous close of $3.45. BioAtla, Inc lost -$0.36 in the last trading session, representing a -10.43% loss.
What is BioAtla, Inc (BCAB) current market capitalization?
BioAtla, Inc market cap is approximately 5.13 million.
What is BioAtla, Inc (BCAB) Earnings Per Share (EPS)?
The trailing EPS is -$41.68, and the forward EPS is -$1.34.
What is BioAtla, Inc (BCAB) EBITDA?
BioAtla, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.22 million.
Does BioAtla, Inc (BCAB) pay dividends?
No. BioAtla, Inc does not pay a dividend.
What is BioAtla, Inc (BCAB) beta (volatility) score?
BioAtla, Inc has a beta of 0.758, indicating lower volatility than the overall market.
